Related Experiment Videos
Phase II trial of titanocene dichloride in advanced renal-cell carcinoma
G Lümmen1, H Sperling, H Luboldt
1Department of Urology, University of Essen, Medical School, Germany.
Cancer Chemotherapy and Pharmacology
|October 15, 1998
Abstract:
Titanocene dichloride was capable of inhibiting the growth of different types of human tumors in vitro. A total of 14 patients with metastatic renal-cell carcinoma (RCC) received 270 mg/m2 titanocene dichloride every 3 weeks for 6 weeks. Although the toxicities and side effects encountered were mild to moderate, no partial or complete response was detectable. In conclusion, titanocene dichloride has no advantage in the therapy of RCC.